PARP2 - poly(ADP-ribose) polymerase 2 Gene

Also Known as ARTD2; ADPRT2; PARP-2; ADPRTL2; ADPRTL3; pADPRT-2

Species: Homo sapiens

Gene Type: protein coding

Gene ID: 10038

About PARP2

Cytogenetic location: 14q11.2 Genomic coordinates (GRCh38): 14:20,343,635-20,357,904 (from NCBI)

This gene has 11 transcripts (splice variants), 185 orthologues and 2 paralogues. Ubiquitous expression in brain (RPKM 14.3), testis (RPKM 13.0) and 25 other tissues.

Summary

This gene encodes poly(ADP-ribosyl)transferase-like 2 protein, which contains a catalytic domain and is capable of catalyzing a poly(ADP-ribosyl)ation reaction. This protein has a catalytic domain which is homologous to that of poly (ADP-ribosyl) transferase, but lacks an N-terminal DNA binding domain which activates the C-terminal catalytic domain of poly (ADP-ribosyl) transferase. The basic residues within the N-terminal region of this protein may bear potential DNA-binding properties, and may be involved in the nuclear and/or nucleolar targeting of the protein. Two alternatively spliced transcript variants encoding distinct isoforms have been found. [provided by RefSeq, Jul 2008]

PARP2 Products (5)

mRNA	Protein	Name
NM_005484.4	NP_005475.2	poly [ADP-ribose] polymerase 2 isoform 1
XM_005267247.4	XP_005267304.1	poly [ADP-ribose] polymerase 2 isoform X1
XM_047430869.1	XP_047286825.1	poly [ADP-ribose] polymerase 2 isoform X3
XM_017020912.2	XP_016876401.1	poly [ADP-ribose] polymerase 2 isoform X2
NM_001042618.2	NP_001036083.1	poly [ADP-ribose] polymerase 2 isoform 2

Gene Ontology

Molecular Function
Biological Process
Cellular Component

Molecular Function GO Annotation	Evidence	References	Source
enables NAD DNA ADP-ribosyltransferase activity	IDA IDA: Inferred from direct assay	27471034	GOA
enables NAD+-protein ADP-ribosyltransferase activity	IDA IDA: Inferred from direct assay	25043379	GOA
enables NAD+-protein poly-ADP-ribosyltransferase activity	IDA IDA: Inferred from direct assay	30104678	GOA
enables NAD+-protein-aspartate ADP-ribosyltransferase activity	IDA IDA: Inferred from direct assay	25043379	GOA
enables NAD+-protein-glutamate ADP-ribosyltransferase activity	IDA IDA: Inferred from direct assay	25043379	GOA
enables NAD+-protein-serine ADP-ribosyltransferase activity	IDA IDA: Inferred from direct assay	28190768	GOA
enables chromatin binding	IDA IDA: Inferred from direct assay	32939087	GOA
enables damaged DNA binding	IDA IDA: Inferred from direct assay	34108479	GOA
enables nucleosome binding	IDA IDA: Inferred from direct assay	32939087	GOA
enables poly-ADP-D-ribose binding	IDA IDA: Inferred from direct assay	30104678	GOA
enables poly-ADP-D-ribose modification-dependent protein binding	IDA IDA: Inferred from direct assay	30104678	GOA
enables protein binding	IPI IPI: Inferred from physical interaction	21812934	GOA

Biological Process GO Annotation	Evidence	References	Source
involved in DNA ADP-ribosylation	IDA IDA: Inferred from direct assay	27471034	GOA
involved in DNA damage response	IDA IDA: Inferred from direct assay	34108479	GOA
involved in DNA repair	IDA IDA: Inferred from direct assay	30104678	GOA
involved in DNA repair-dependent chromatin remodeling	IDA IDA: Inferred from direct assay	32939087	GOA
involved in protein auto-ADP-ribosylation	IDA IDA: Inferred from direct assay	32939087	GOA
involved in protein poly-ADP-ribosylation	IDA IDA: Inferred from direct assay	25043379	GOA

Cellular Component GO Annotation	Evidence	References	Source
located in nucleolus	IDA IDA: Inferred from direct assay	15615785	GOA
located in nucleoplasm	IDA IDA: Inferred from direct assay	15615785	GOA
located in nucleus	IDA IDA: Inferred from direct assay	26704974	GOA
is active in site of DNA damage	IDA IDA: Inferred from direct assay	30104678	GOA
located in site of DNA damage	IDA IDA: Inferred from direct assay	26704974	GOA

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

PARP2 Protein Structure

WGR

PARP_reg

PARP

0
100
200
300
400
500
583 a.a.

Protein Preferred Names	Protein Names
poly [ADP-ribose] polymerase 2	ADP-ribosyltransferase (NAD+ poly(ADP-ribose) polymerase)-like 2 ADP-ribosyltransferase diphtheria toxin-like 2 ADPRT-2 DNA ADP-ribosyltransferase PARP2 NAD(+) ADP-ribosyltransferase 2 hPARP-2 poly (ADP-ribose) polymerase family, member 2 poly (ADP-ribosyl) transferase-like 2 poly[ADP-ribose] synthase 2 poly[ADP-ribose] synthetase 2 protein poly-ADP-ribosyltransferase PARP2

PARP2 Protein-protein interaction Information

Type	Protein Name	Protein ID	Interactor	Interactor Species	Interactor ID	Detection Method	References
Intra	PARP2	Q9UGN5	FKBP3	Homo sapiens	Q00688	Protein Array	21812934
Intra	PARP2	Q9UGN5	FKBP3	Homo sapiens	Q00688	Enzymatic Study	21812934
Intra	PARP2	Q9UGN5	APLF	Homo sapiens	Q8IW19	Protein Array	21812934
Intra	PARP2	Q9UGN5	HMGN2	Homo sapiens	P05204	Protein Array	21812934
Intra	PARP2	Q9UGN5	STAC	Homo sapiens	Q99469	Enzymatic Study	21812934
Intra	PARP2	Q9UGN5	STAC	Homo sapiens	Q99469	Protein Array	21812934

Cross: Cross-species interaction Intra: Intraspecies interaction

PARP2 Antibodies

Cat. No.	Product Name	Application	Reactivity
HY-P80265	PARP2 Antibody (YA244)	WB, FC	Human

Related Diseases

Diseases	Alias
Fanconi Anemia, Complementation Group A	Fanconi Anemia Fanconi Pancytopenia Fanconi Anemia Complementation Group A FANCA Fa Fanconi Panmyelopathy Fanconi'S Anemia Fanconi Anaemia Fanconi'S Anaemia Fanconi Hypoplastic Anemia Estren-Dameshek Variant Of Fanconi Anemia Estren-Dameshek Variant Of Fanconi Pancytopenia Fanconi Anemia Estren-Dameshek Variant Fanconis Anemia
Fallopian Tube Carcinoma	Fallopian Tube Cancer Cancer Of The Fallopian Tube Carcinoma Of Fallopian Tube Neoplasm Of Fallopian Tube Fallopian Tube Neoplasms Fallopian Tube Ca Fallopian Tube Neoplasm Malignant Neoplasm Of Uterine Tube Malignant Tumor Of Fallopian Tube Malignant Tumour Of Fallopian Tube Tumor Of The Fallopian Tube Tumor, Fallopian Tube, Malignant Malignant Tumor Of Fallopian Tubes Cancer Of Fallopian Tubes Malignant Tubal Tumor Tubal Cancer Malignant Neoplasm Of Fallopian Tube Primary Malignant Neoplasm Of Fallopian Tube Cancer Of The Oviduct
Hereditary Breast Ovarian Cancer Syndrome	Hereditary Breast And Ovarian Cancer Syndrome Brca1- And Brca2-Associated Hereditary Breast And Ovarian Cancer Breast And/Or Ovarian Cancer Breast And Ovarian Cancer Syndrome Hboc Syndrome Hereditary Breast And Ovarian Cancer Brca1- Brca2-Associated Hboc
Osebold-Remondini Syndrome	Brachydactyly Type A6 Brachymesophalangy With Mesomelic Short Limbs And Carpal And Tarsal Osseous Abnormalities Bda6 Brachydactyly, Type A6
Neurodegeneration, Childhood-Onset, Stress-Induced, With Variable Ataxia And Seizures	CONDSIAS Stress-Induced Childhood-Onset Neurodegeneration With Variable Ataxia And Seizures
Fallopian Tube Disease	Fallopian Tube Diseases

Diseases	Alias
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

Related Agents

Approval
Clinical Phase
Pre-clinical Phase

Approval

Bioactive Molecules (13)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-10162	Olaparib	Inhibitor	99.98%	Yes
HY-16106	Talazoparib	Inhibitor	99.89%	Unkown
HY-10619	Niraparib	Inhibitor	99.96%	Yes
HY-10617A	Rucaparib	Inhibitor	99.96%	Yes
HY-10619A	Niraparib hydrochloride	Inhibitor	99.41%	Yes
HY-10617	Rucaparib phosphate	Inhibitor	99.76%	Yes
HY-10619B	Niraparib tosylate	Inhibitor	99.99%	Yes
HY-102003	Rucaparib monocamsylate	Inhibitor	99.91%	Yes
HY-10619E	Niraparib tosylate hydrate	Inhibitor	99.97%	Yes
HY-102003A	Rucaparib camsylate	Inhibitor	/	Unkown
HY-10617C	Rucaparib tartrate	Inhibitor	/	Unkown
HY-10617D	Rucaparib acetate	Inhibitor	/	Unkown
HY-10617B	Rucaparib hydrochloride	Inhibitor	/	Unkown

Clinical Phase

Bioactive Molecules (10)

Cat. No.	Product Name	Effect	Purity	Phase
HY-122661	Mefuparib hydrochloride	Inhibitor	98.62%	Phase 4
HY-132167	Saruparib	Inhibitor	99.76%	Phase 3
HY-10129	Veliparib	Inhibitor	99.77%	Phase 3
HY-10130	Veliparib dihydrochloride	Inhibitor	99.98%	Phase 3
HY-12418	Stenoparib	Inhibitor	98.0%	Phase 2
HY-137457A	Venadaparib hydrochloride	Inhibitor	/	Phase 2
HY-105303	CEP-9722	Inhibitor	/	Phase 2
HY-13536	AZD-2461	Inhibitor	99.79%	Phase 1
HY-115552	Simmiparib	Inhibitor	99.01%	Phase 1
HY-170432	PARP1-IN-34	Inhibitor	/	Phase 1

Pre-clinical Phase

Bioactive Molecules (59)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-15147	XAV-939	Inhibitor	99.91%	Unkown
HY-13688A	PJ34	Inhibitor	99.66%	Unkown
HY-13990	NVP-TNKS656	Inhibitor	99.68%	Unkown
HY-148566	OUL232	Inhibitor	99.86%	Unkown
HY-14478	UPF 1069	Inhibitor	99.02%	Unkown
HY-150207	RBN-3143	Inhibitor	99.29%	Unkown
HY-13688	PJ34 hydrochloride	Inhibitor	99.81%	Unkown
HY-137457	Venadaparib	Inhibitor	98.11%	Unkown
HY-100225	ME0328	Inhibitor	99.64%	Unkown
HY-75706	N-Descyclopropanecarbaldehyde Olaparib	Inhibitor	99.46%	Unkown
HY-12975	AZ6102	Inhibitor	99.53%	Unkown
HY-145584	Nesuparib	Inhibitor	99.54%	Unkown
HY-19351	MN-64	Inhibitor	99.61%	Unkown
HY-108632	BYK204165	Inhibitor	99.89%	Unkown
HY-18954	NMS-P118	Inhibitor	99.54%	Unkown
HY-156419	PARP7-IN-16	Inhibitor	99.91%	Unkown
HY-156419A	PARP7-IN-16 free base	Inhibitor	99.40%	Unkown
HY-148754	PARP10-IN-3	Inhibitor	98.72%	Unkown
HY-132297A	PARP1-IN-5 dihydrochloride	Inhibitor	97.56%	Unkown
HY-149800	PARP-1-IN-3	Inhibitor	99.80%	Unkown
HY-10614	A-966492	Inhibitor	99.00%	Unkown
HY-145749	PARPYnD	Inhibitor	98.86%	Unkown
HY-147886	PARP1-IN-11	Inhibitor	99.42%	Unkown
HY-155993	YCH1899	Inhibitor	99.39%	Unkown
HY-148753	PARP10-IN-2	Inhibitor	98.02%	Unkown
HY-133124	PARP/PI3K-IN-1	Inhibitor	99.40%	Unkown
HY-121719	TIQ-A	Inhibitor	99.85%	Unkown
HY-183013	PROTAC PARP2 degrader-1	Degrader	95.86%	Unkown
HY-105692	DR2313	Inhibitor	99.66%	Unkown
HY-185459	PCIP-1	Inhibitor	98.80%	Unkown
HY-102035	PARP-2-IN-1	Inhibitor	99.56%	Unkown
HY-146336	PARP1/2/TNKS1/2-IN-1	Inhibitor	98.66%	Unkown
HY-143338	ART-IN-1	Inhibitor	98.91%	Unkown
HY-176713	KWZY-11	Inhibitor	/	Unkown
HY-130646	iVeliparib-AP6	Degrader	/	Unkown
HY-132297	PARP1-IN-5	Inhibitor	/	Unkown
HY-145584A	Nesuparib hydrochloride	Inhibitor	/	Unkown
HY-W294889	OUL245	Inhibitor	/	Unkown
HY-105253	PARP-2/1-IN-2	Inhibitor	/	Unkown
HY-14687	(rac)-Talazoparib	Inhibitor	/	Unkown
HY-158334	NDs-IN-1	Inhibitor	/	Unkown
HY-168851	PARP1-IN-35	Inhibitor	/	Unkown
HY-181928	PARP1/c-Met-IN-3	Inhibitor	/	Unkown
HY-180809	YCH3292	Inhibitor	/	Unkown
HY-179406	PARP1-IN-49	Inhibitor	/	Unkown
HY-151625	PARP-2-IN-3	Inhibitor	/	Unkown
HY-161606	PARP-1/2/7-IN-1	Inhibitor	/	Unkown
HY-179386	PARP1/EZH2-IN-1	Inhibitor	/	Unkown
HY-181265	PARP1-IN-53	Inhibitor	/	Unkown
HY-179020	PARP/VEGFR3-IN-1	Inhibitor	/	Unkown
HY-174828	ATR/PARP1-IN-1	Inhibitor	/	Unkown
HY-100847	AZ0108	Inhibitor	/	Unkown
HY-171543	PARP1-IN-37	Inhibitor	/	Unkown
HY-178032	PARP1-IN-44	Inhibitor	/	Unkown
HY-179349	PARP-1/2-IN-5	Inhibitor	/	Unkown
HY-169299	TOPOI/PARP-1-IN-2	Inhibitor	/	Unkown
HY-182246	MC2050	Inhibitor	/	Unkown
HY-172747	TNKS-2-IN-3	Inhibitor	/	Unkown
HY-14477	UPF-1035	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Bos taurus	PARP2	VGNC	VGNC:53577
Felis catus	PARP2	VGNC	VGNC:80893
Rattus norvegicus	PARP2	RGD	RGD:1310568
Macaca mulatta	PARP2	VGNC	VGNC:84417
Canis familiaris	PARP2	VGNC	VGNC:54219
Mus musculus	PARP2	MGD	MGI:1341112
Others	PARP2	NCBI